and inhibition as treatment strategies in V600E metastatic colorectal cancer

and inhibition as treatment strategies in V600E metastatic colorectal cancer

Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival....

Full description

Bibliographic Details
Main Authors: Javier Ros, Iosune Baraibar, Emilia Sardo, Nuria Mulet, Francesc Salvà, Guillem Argilés, Giulia Martini, Davide Ciardiello, José Luis Cuadra, Josep Tabernero, Elena Élez
Format: Article
Language:English
Published: SAGE Publishing 2021-02-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835921992974

Internet

https://doi.org/10.1177/1758835921992974

Similar Items